Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/EBITDA
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBITDA returns to its 3-Year Average (40.4), the stock would be worth ¥166.57 (16% upside from current price).
| Scenario | EV/EBITDA Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 34.9 | ¥144.11 |
0%
|
| 3-Year Average | 40.4 | ¥166.57 |
+16%
|
| 5-Year Average | 52.3 | ¥215.61 |
+50%
|
| Industry Average | 23.9 | ¥98.61 |
-32%
|
| Country Average | 28.8 | ¥118.9 |
-17%
|
Forward EV/EBITDA
Today’s price vs future ebitda
| Today's Enterprise Value | EBITDA | Forward EV/EBITDA | ||
|---|---|---|---|---|
|
¥100.1B
|
/ |
Oct 2025
¥2.5B
|
= |
|
|
¥100.1B
|
/ |
Dec 2025
¥3.5B
|
= |
|
|
¥100.1B
|
/ |
Dec 2026
¥3.9B
|
= |
|
|
¥100.1B
|
/ |
Dec 2027
¥4.6B
|
= |
|
Forward EV/EBITDA shows whether today’s EV/EBITDA still looks high or low once future ebitda are taken into account.
Peer Comparison
| Market Cap | EV/EBITDA | P/E | ||||
|---|---|---|---|---|---|---|
| CN |
|
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
|
86.9B CNY | 34.9 | 35.9 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
853.2B USD | 28 | 41.3 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
544.6B USD | 16.6 | 25.9 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 11.7 | 19.8 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
225.8B GBP | 16.2 | 29.2 | |
| CH |
|
Novartis AG
SIX:NOVN
|
226.8B CHF | 12.4 | 20 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
278.5B USD | 9.5 | 15.3 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 386.8 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 7.9 | 10.7 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
155.3B USD | 7.7 | 20 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
119.6B USD | 7.2 | 17 |
Market Distribution
| Min | 0 |
| 30th Percentile | 16.3 |
| Median | 28.8 |
| 70th Percentile | 53.1 |
| Max | 49 021 |
Other Multiples
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
Glance View
Zhangzhou Pientzehuang Pharmaceutical Co. Ltd., nestled in the heart of Fujian Province, China, is a firm steeped in history and tradition, yet thriving in today’s modern pharmaceutical landscape. The company is best known for its signature product, Pientzehuang Pills, a centuries-old traditional Chinese medicine believed to offer hepatoprotective and detoxifying properties. Rooted in ancient formulations, Pientzehuang Pills are celebrated for their efficacy in addressing liver ailments and enhancing overall vitality. This has secured their place as a staple in Chinese households, maintaining cultural resonance while appealing to a broader audience through the global rise in demand for alternative medicine. The firm operates with a delicate balance, integrating traditional Chinese medicine practices with increasingly sophisticated production technologies to ensure quality consistency and scalability. Zhangzhou Pientzehuang leverages its brand heritage and expertise in traditional herbal remedies to drive revenue. The company has adeptly positioned itself within both domestic and international markets, capitalizing on the growing interest in holistic health approaches. By focusing on research and development, the company continues to innovate, expanding its product line to include health supplements and preventive solutions that cater to modern health challenges. Its strategic distribution channels, including hospitals, pharmacies, and online platforms, enable broad market penetration, ensuring robust sales growth. This dual strategy of preserving the traditional while embracing the modern allows the company to keep its legacy relevant in a competitive pharmaceutical industry, thereby securing its stronghold in the market and ensuring sustained financial performance.